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Pretargeted immunoscintigraphy in patients with medullary thyroid
carcinoma
P Magnani, G Paganelli*, C Songini, A Samuel, F Sudati, AG Siccardi and F Fazio
INB-CNR, Institute H San Raffaele, University of Milan, Milan, Italy.
Summary To evaluate the use of pretargeted immunoscintigraphy (ISG) in the diagnosis and follow-up of
patients with medullary thyroid carcinoma (MTC), we studied 25 patients with histologically proven disease;
ISG was repeated after surgery in two patients. The antibody, either an anticarcinoembryonic antigen (CEA) or
an antichromogranin A (CgA) biotinylated monoclonal antibody (MAb) or a cocktail of the two biotinylated
MAbs was first injected. After 24 h, avidin was administrated i.v., followed by "'In-labelled biotin 24 h later.
Fifty-two lesions were visualised. Six primary tumours, diagnosed by increased calcitonin levels, were all
correctly diagnosed; 47 recurrences, also suspected by blood tumour markers, were detected and confirmed by
cytology or histology. In one case, single photon emission tomography allowed the detection of small lymph
nodes with a diameter of 4-7 mm. These lesions, not judged neoplastic by ultrasound, were confirmed to be
neoplastic by fine needle aspiration. Pretargeted ISG correctly localises primary tumours and recurrences in
MTC patients, when the only marker of relapse is serum elevation of calcitonin. With this three-step
pretargeting method, cocktails ofpotentially useful MAbs can be used, avoiding false-negative studies that may
occur when CEA or CgA are not expressed.
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Medullary thyroid carcinoma (MTC) arises from calcitonin-
secreting parafollicular cells in the thyroid. Both the sporadic
and the familial form are treated by surgery (Chong et al.,
1975; Rossi et al., 1980), as the efficacy of radiotherapy is
limited (Samaan et al., 1988) and chemotherapy is ineffective
(Rougier et al., 1983; Brunt and Wells, 1987). Early diagnosis
of recurrence or metastasis and accurate localisation of
recurrent disease are very important prerequisites for
successful surgical excision.
Elevated serum calcitonin (Ct) is considered to be a
marker for MTC. High serum levels of Ct and carcinoem-
bryonic antigen (CEA) can often be found in patients with
recurrent disease several years before it becomes clinically
apparent, but, at present, no efficient and specific method is
available for the localisation of recurrences.
Morphological imaging techniques (ultrasonography, US;
computerised tomography, CT; magnetic resonance imaging,
MRI) are routinely used to confirm and localise a biologically
detected recurrence but are not always adequate because of
topographic polymorphism and the small size of tumour
recurrences at an early stage of development (Schwerk et al.,
1985; Frank et al., 1987; Crow et al., 1989).
Several methods based on tumour avidity of non-specific
radiopharmaceuticals such as [99"Tc](V)DMSA, '3I11231-MIBG
and 20'T1 have also been designed for this purpose, with
variable results (Arnstein et al., 1986; Hilditch et al., 1986;
Baulieu et al., 1987; Clarke et al., 1987; Hilditch, 1987;
Clarke et al., 1988; Hoefnagel et al., 1988; Guerra et al.,
1989; Adams et al., 1990; Charkes et al., 1990; Udelsman et
al., 1993).
In the attempt to specifically localise tumour in vivo, MAbs
directed to tumour-associated antigens and labelled with
gamma-emitting isotopes can be used (Goldenberg et al.,
1980; Larson, 1985). The sensitivity of this technique can be
enhanced by lowering the background with tumour pretarget-
ing strategies (Hnatowich et al., 1987; Goodwin et al., 1988;
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Rowlinson et al., 1988; Domogatsky, 1989; Le Doussal et al.,
1989; Kalofonos et al., 1990; Peltier et al., 1993). When tumour
targeting is separated from injection ofthe radiolabel, injection
of the radiotracer can be delayed to a time when circulating
MAbs are removed from the blood and consequently back-
ground activity is low. Some of these strategies have the
potential additional advantage of being able to target the
tumour with different antibodies at the same time. One ofthese
strategies, based on the avidin-biotin system, involves the
injection of biotinylated MAbs (first step), followed by avidin
administration (second step) to precipitate circulating biotiny-
lated MAbs and, at the same time, to target the tumourcells for
adequate homing in of the subsequently radiolabelled biotin
(third step) (Paganelli et al., 1991). In this case a cocktail of
MAbs could be injected i.v. as first step.
Positive immunohistochemical stains for Ct and CEA are
characteristic of MTC (De Lellis et al., 1978; Talerman et al.,
1979; Pacini et al., 1991). Recent immunohistochemical
studies have established that MTC also stains positively for
chromogranin A (CgA) (Schmid et al., 1987), a glycoprotein
stored and released by exocytosis together with the resident
hormones of electron-dense core secretory granules in
apudomas.
This paper reports the evaluation of pretargeted immu-
noscintigraphy (ISG) in the diagnosis of primary/metastatic
and recurrent MTC. As antibodies, anti-CEA and anti-CgA
(separately and as a cocktail) biotinylated MAbs were used in
a three-step procedure.
Materials and methods
Patients
A continuous sequence of 25 patients attending endocrine
and oncological clinics in various Italian cities and with a
clinical diagnosis of MTC (ten female, 15 male; 18-68 years
of age) were enrolled in the study, which was approved by
the Scientific Institute HS Raffaele Ethics Committee. Before
entering the study all patients gave written informed consent.
Six patients had primary tumour diagnosed by biochem-
ical data and a family history of MTC. All six patients
underwent surgery.
Eighteen patients had biochemical evidence of recurrence
and one patient had US evidence of a thyroid remnant withMTC pretargeted immunoscintigraphy
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Table I Clinical patient data
Age (years)/ Familial (F)!
Patients sex (M/F) sporadic (S)
2
3
4
S
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
49/F
43/M
51/M
32/M
19/F
60/M
36/F
28/M
29/M
18/F
40/M
53/M
22/M
22/F
24/F
29/M
46/F
26/F
54/M
46/M
32/M
22/F
29/M
34/M
68/F
S
S
F
S
S
S
F
F
S
F
F
F
F
S
F
F
S
F
S
F
F
F
F
F
S
New case (NC)/
Syndrome Recurrence (R)
MEN2A
MEN2B
MEN2A
MEN2A
MEN2A
MEN2A
MEN2A
MEN2A
MEN2A
MEN2A
MEN2A
R
R
R
R
R
R
NC
R
NC
NC
NC
NC
NC
R
R
R
R
R
R
R
R
R
R
R
Normal value (IRMA): Ct< 10 pg ml-'; CEA<5 ng ml-1. aSerum levels elevated or normal. NA, not available.
normal Ct serum levels following surgical treatment of their
primary tumour. They underwent either fine needle aspiration
(FNA) (five patients) or surgical intervention (14 patients) of
all the lesions visualised by ISG.
Histopathological diagnosis (HIS) was always assessed on
paraffin sections when surgery was available and on cytology
when FNA had been performed.
ISG was repeated in two patients following surgery.
Clinical patient data are reported in Table I.
Reagents
MAb F023C5 (IgGI) (Sorin Biomedica, Saluggia, Italy)
reacts with the protein portion of the CEA molecule with
an affinity constant (Ka) of 7 x 108 M'-. It has already been
described and extensively used in ISG (Buraggi et al., 1987;
Gasparrini et al., 1988; Siccardi et al., 1989).
MAb Al1 (IgG1) is a monoclonal antibody directed
against human CgA that does not react with CgB and
CgC. It was obtained by immunisation of Balb/c mice with
human phaeochromocytoma-derived chromaffin granules and
screening of hybridoma supernatants by enzyme-linked
immunoassay (ELISA) on crude chromogranin prepara-
tions. MAb All was characterised by two-dimensional
immunoblotting and immunohistochemistry (Pelagi et al.,
1989) but Ka is not yet defined.
MAbs were biotinylated by Societ'a Prodotti Antibiotici
(S.P.A., Milano, Italy) as previously described (Paganelli et
al., 1991). The degree of biotinylation was 5+ 1 biotin per
antibody determined spectrophotometrically, after protein
digestion, as described (Hnatowich et al., 1987). At this grade
of biotinylation the retained immunoreactivity of the
antibodies was more than 90%, as tested in a standard
ELISA system (Paganelli et al., 1991).
Pure hen egg avidin was obtained from S.P.A. DTPA-
conjugated biotin was purchased from Sigma (St Louis, MO,
USA).
Radiolabelling
DTPA-conjugated biotin was diluted in phosphate-buffered
saline (PBS), pH 7.4, at a concentration of 2 pg pl-'. The
solution was sterilised by 0.22 pum Millipore filtration. "'InCl3
was diluted in citrate buffer (0.02 M; pH 6.5) to
740 kBq pl-'. The reagents were then mixed and allowed to
react at room temperature for 10 min. More than 98% of
"'In was bound to the conjugate, as shown by paper
chromatography performed with Whatman no. 1 and
bicarbonate buffer 0.05 M as liquid phase. The ability to
bind avidin after labelling was verified by fast protein liquid
chromatography (FPLC) (Pharmacia, Sweden), by mixing
["'In]biotin with an appropriate amount of avidin. No loss of
reactivity was observed.
Toxicity and immunogenicity
All patients were closely observed for 2 h following
administration of avidin. Blood samples (10 ml) were
obtained in appropriate tubes just before the administration
of avidin, then 10- 15 days following the injection. All
samples were sent out both for routine blood tests as well as
to assess the human anti-mouse immunoglobulin (HAMA)
and anti-avidin response (HAAR).
The induction of human anti-mouse immunoglobulin
antibodies was investigated using an ELISA system
(Seccamani et al., 1989) in only 11 patients. In fact, our
patients being a continuous sequence of patients attending
endocrine and oncological clinics of various cities in Italy,
they were not always willing to come back for blood tests. In
these patients, avidin immunogenicity was studied on
microwell plates coated with avidin or streptavidin sepa-
rately. The plates were saturated for 1 h with PBS/3% bovine
serum albumin (BSA). Human sera dilutions were added and
incubated for 1 h at 37°C. After five washes, the binding of
human anti-avidin antibodies was revealed with horseradish
peroxidase-conjugated rabbit anti-human Ig antibodies
(Dako) diluted 1:1000, for 45 min at 37°C. After six
washes, the enzymatic reaction was developed with a
chromogenic substrate (o-phenylendiamine; Sorin Biomedi-
ca, Saluggia, Italy) for 10 min and blocked by addition of
1 M sulphuric acid. The optical density reading was 492 nm.
ISG study
The three-step protocol used has been described previously
(Paganelli et al., 1991). Briefly: 1 mg of biotinylated MAb
Biochemical
Ct b/s
20; 210
25; 230
15; 300
50; 700
13; 300
647; 3000
125; 2000
1700; 3055
24; 430
22; 205
13; 320
50; 400
150; 3000
314; 1700
513; 3300
671; 3900
530; 2900
6; n.a.
700; 2320
156; 1500
20; 220
70; 400
1600; 2424
189; 1900
160; 1800
data
CEAa
Elevated
Elevated
Normal
Elevated
Elevated
Elevated
Normal
Elevated
Normal
Normal
Normal
Elevated
Normal
Elevated
Normal
Elevated
NA
NA
Elevated
Normal
Elevated
Elevated
Elevated
Elevated
Elevatedwas injected i.v. over 2 min (first step). The biotinylated
F023C5 MAb was used in 16 ISG studies, the biotinylated
All MAb in seven studies, whereas in four studies, a cocktail
of biotinylated F023C5 and All MAbs (0.5 mg+0.5 mg)
was administered. After 24 h, 1 mg of unlabelled avidin was
injected i.v. over 2 min, followed by an additional 9 mg
15 min later (second step). The aim of these two avidin
administrations is to precipitate circulating biotinylated
antibodies (1 mg) and subsequently to target the biotinylated
MAbs bound on tumour cells (9 mg) (Schmid et al., 1987;
Buraggi et al., 1987; O'Byrne et al., 1992). ['I11n]biotin
(200 jug) (111 - 185 MBq) was injected i.v. 24 h after the
administration of cold avidin in 3 ml of saline solution in a
bolus injection (third step).
Within 1-3 h after the [11 In]biotin injection, a single
photon emission tomography (SPET) study (64 x 64 pixel
matrix, 64 projections over 3600) of the neck and planar spot
views (64 x 64 pixel matrix, 150 Kcounts-view) of the neck,
chest and abdomen were acquired. Indeed, as the label is a
small molecule, background radioactivity levels are drasti-
cally reduced, and imaging can be performed shortly after
injection of the radiolabel.
Images were obtained using a 40 cm circular field rotating
gamma-camera (7500 Orbiter, Siemens), linked to a
Microvax II computer (Siemens) and equipped with a
high-energy collimator and by selecting two 15% energy
windows centered over the 173 and 247 keV photopeaks of
I 'In.
Tomographic images were reconstructed with a filtered
back projection algorithm and Hann filter (cut-off 0.5/pixel).
Planar and tomographic images were evaluated for the
presence or absence of pathological tracer accumulation by
two independent observers who are unaware of the clinical
problem and the biochemical tumour marker levels. A
semiquantitative visual analysis was carried out on planar
and tomographic images by dividing the neck region into
three sections (left laterocervical, median and right latero-
cervical). The ISG studies were visually scored; the score
ranged from 0 to 2 (0 =absent tracer uptake; 1 =doubtful
tracer uptake; 2 =pathological tracer uptake). The statistical
MTC pretargeted immunoscintigraphy
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analysis was carried out on the scores of tracer uptake from
the three sections considered. A kappa test (Fleiss, 1980) was
used to test inter-observer agreement.
Results
No toxicity was observed. Out of the 11 patients tested, one
developed a weak antibody response against mouse
immunoglobulins whereas six patients demonstrated anti-
avidin antibodies 10 -15 days after injection.
The kappa test demonstrated a strong agreement between
the two observers (K>0.75) both for planar and for
tomographic images.
ISG results were classified as true positive (TP), true
negative (TN), false positive (FP) and false negative (FN)
according to histological diagnosis.
ISG results, final diagnoses and classifications are reported
in Table II.
Figure 1 reports the overall distribution of activity in a
typical patient. Activity biodistribution in the three-step
pretargeting method using anti-CEA MAbs was compared
with that obtained in the conventional ISG using the same
antibody as Paganelli et al. (1991). No liver uptake and a
negligible bone marrow uptake were demonstrated.
Fifty-two lesions were visualised by SPET and all verified
by histology or cytology. Only three of these 52 lesions were
visualised on planar spot views (patients 2, 16 and 23).
Fifty lesions were TP and two FP. In these two cases
(patients 20, 21), metastatic lymph nodes visualised by ISG
were not found at surgery. The smallest lesion detected by
SPET was a right laterocervical lymph node of 4 mm in
diameter. Two lymph nodes (patients 6, 21) identified as
MTC metastases at histology were not visualised by ISG (two
FN).
As regards patient 9 (TN, Table II), he had an abnormal
Ct response to pentagastrin stimulation; ISG study did not
show abnormal thyroid uptake of the tracer. The patient
underwent surgery, and histology revealed a nodular
hyperplasia as a colloid goiter.
Table II ISG results, final diagnoses and classifications
MAb ISG sites of
Patients (F)/(A)/(FA) tracer uptake Final diagnosis HIS Classification
1 F R FNA MTC 1 TP
2 F 2 left LC FNA MTC 2 TP
3 F 2 right LC FNA MTC 2 TP
4 F 2 right L:C FNA MTC 2 TP
5 F R Histology MTC 1 TP
6 F R + 1 left LC Histology MTC 2 TP, 1 FN
7 F Thyroid Histology MTC 1 TP
8 F 1 left + 1 right LC Histology MTC 2 TP
9 F Negative scan Histology NH 1 TN
10 F Thyroid Histology MTC 1 TP
11 F Thyroid Histology CCH 1 TP
12 F Thyroid + 3 right LC Histology MTC 4 TP
13 F Thyroid Histology MTC 1 TP
14 F R Histology MTC 1 TP
15 A R + I right LC Histology MTC 2 TP
16 A 2 right LC Histology MTC 2 TP
17 A R + 1 right LC Histology MTC 2 TP
18 A R + 2 left LC Histology MTC 3 TP
19 A R + 2 left, 3 right LC Histology MTC 6 TP
20 A R + 3 left LC Histology MTC 3 TP, 1 FP
21 A R +l right LC FNA MTC I TP, 1 FP, 1 FN
22 FA 2 left, 1 right LC Histology MTC 3 TP
23 FA R + 1 left, 1 right LC Histology MTC 3 TP
24 FA 2 right LC Histology MTC 2 TP
25 FA 2 right LC Histology MTC 2 TP
Total 11 R, 5 thyroid, 36 LC 50 TP, 1 TN, 2 FP, 2 FN
MAb, (F)F023C5; (A)Al1; (FA) F023C5 + Al1. NH, nodularhyperplasia; CCH, C-cell hyperplasia; R, remnant;
LC, laterocervical lymph nodes.MTC pretargeted immunoscintigraphy
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The two follow-up ISG studies correctly identified the
presence of malignant tissue.
Patient 7 had a primary MTC with elevated Ct serum
levels and a first positive ISG study. The tumour was
removed by surgery, and histology confirmed two MTC foci.
Immunohistochemical staining was highly positive for CEA.
Ct serum levels returned to normal post-operatively (basal
and in response to pentagastrin stimulation) and post-
operative ISG showed no cervical accumulation.
Patient 4, who had biochemical evidence of recurrence
following surgical treatment of his primary MTC, underwent
a first ISG study that showed a pathological tracer uptake in
the right region of the neck. US did not confirm a
laterocervical involvement and FNA was inadequate. ISG
was repeated about 4 months later and an abnormal tracer
uptake was still evident in some right laterocervical lymph
nodes. FNA was also repeated and cytology confirmed the
presence of metastases of MTC.
Four patients who underwent anti-CEA ISG study had
normal CEA serum level and a TP scan. In particular, patient
11 with C-cell hyperplasia had a positive ISG study. This
patient, with a family history of MEN2A and elevated Ct
serum levels in response to pentagastrin stimulation, under-
went total thyroidectomy. Histology revealed diffuse C-cell
hyperplasia with an immunohistochemical stain positive for
CEA. On the other hand, patient 18 had normal Ct serum
levels, but US revealed a thyroid remnant. ISG showed a
strong uptake of the tracer not only in the residual thyroid
but also in some left laterocervical lymph nodes (Figure 2).
The patient underwent surgery and histology confirmed the
presence of metastases of medullary thyroid carcinoma.
Figure 3 illustrates a case of cervical involvement (patient
3) detected by ISG. Immunoscintigraphy revealed a clear
uptake of the tracer in the right region of the neck. Two
small lymph nodes of 4 mm and 11 x 7 mm in diameter, not
detected as neoplastic by US, have been confirmed to be
metastases from MTC by FNA. Moreover, this patient had a
suspicious-looking solid lesion, 20 mm in diameter in the
liver, revealed by US and CT. ISG showed no liver uptake.
Histological control revealed a benign liver lesion (angioma).
Figures 4-6 show examples of planar and SPET images
from patient 15, 18 and 25 respectively.
Discussion
Medullary thyroid carcinoma is an uncommon tumour that
frequently metastasises to cervical and mediastinal lymph
nodes, bone and lung (Brunt and Wells, 1987). Ct and CEA
are very sensitive indicators of MTC and are currently used
as serum markers for relapse or distant metastases after
thyroidectomy. Localisation of the tumour may be a more
Figure 1 Whole-body biodistribution obtained 2h after the
injection of radioactivity. Most of the activity is already excreted
by the kidneys (k) with high levels in the bladder (B). Please note
the absence of activity in the liver and skeleton. Some biotin is
also excreted in the mammary glands (arrow). R, right.
Figure 2 ISG SPET study of patient 18, performed 2h after
radioactivity injection. Transaxial sections go from bottom to top.
A strong uptake of the tracer in the thyroid remnant is clearly
evident in front of the trachea (T), which appears as a cold area
in the transaxial sections. The study also revealed a pathological
uptake in some laterocervical lymph nodes (arrow). Histology
confirmed the presence of metastases of medullary thyroid
carcinoma. R, right.
Figure 3 US study (a) of patient 3: two small lymph nodes, the
larger of them 6 x4mm in diameter, are visible in the right region
of the neck (arrow). Pretargeted ISG coronal sections (b),
performed 2h after [("In]biotin injection. Coronal sections go
from posterior to anterior view. A pathological uptake of the
tracer is evident in the right cervical region (arrows) and
corresponds to cervical lymph nodes. FNA was performed and
cytology confirmed the presence of metastases from MTC. R,
right.complicated problem. US is useful in the post-surgical follow-
up of MTC patients in order to evaluate cervical lymph
nodes and relapse, but it is not specific (Schwerk et al., 1985).
MRI has similar indications and it can also be used in the
evaluation of the mediastinum (Crow et al., 1989). Various
Figure 4 ISG planar image (A) and transaxial sections (B, C)
from patient 18. No pathological tracer uptake is evident on
planar spot view. A pathological tracer uptake is clearly evident
in a left laterocervical lymph node (B, arrow) and in the thyroid
remnant (C, arrow) on SPET sections. R, right.
Figure 5 ISG planar image (A) and transaxial section (B) from
patient 15. A pathological tracer uptake in the thyroid remnant
(arrow) is visible only in the SPET section. R, right.
Figure 6 ISG planar image (A) and coronal section (B) from
patient 25. A pathological tracer uptake in two right
laterocervical lymph nodes (arrows) is visible only in the SPET
section. R, right.
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radiotracers have been proposed for this purpose.
[99mTc](V)DMSA, 1111231_MIBG and 201T1 show different
sensitivities of lesion detection in different reports (Arnstein
et al., 1986; Hilditch et al., 1986, 1987; Baulieu et al., 1987;
Clarke et al., 1987, 1988; Hoefnagel et al., 1988; Adams et al.,
1990; Guerra et al., 1989; Charkes et al., 1990; Udelsman et
al., 1993). These different sensitivities can be related to
patient selection, limited number of patients studied, Ct
blood levels, dimension of lesions studied or to methodolo-
gical problems. For example, Clarke et al. (1987, 1988)
reported a sensitivity of 74% in 19 patients using
[99mTc](V)DMSA, Mojiminiyi et al. (1989) correctly diag-
nosed seven out of eight patients, Hilditch et al. could not
reveal abnormal foci of tracer uptake in any of five MTC
patients in a first work (Hilditch et al., 1987), whereas in a
subsequent work (Hilditch et al., 1988) they correctly
diagnosed three out of four MTC patients. These are
certainly good results; however, they were obtained in too
few patients.
In vivo tumour localisation can be obtained using
radiolabelled monoclonal antibodies directed against tu-
mour-associated antigens. Thus ISG is very specific, but a
relatively low tumour to background ratio and a high
background activity can affect its sensitivity. Theoretically
ISG can target different MTC-associated antigens, such as
Ct, CEA and CgA (De Lellis et al., 1978; Talerman et al.,
1979; Schmid-et al., 1987; Pacini et al., 1991). MTC often
produces CEA, which is expressed both in the cytoplasm and
on the cell membrane. On the contrary, Ct is expressed within
the cytoplasm. In our pretargeting protocol, the most
appropriate target antigen must be available on the cell
surface. This happens because biotinylated MAb binds to the
antigen and becomes, in its turn, the 'antigen' for the cold
avidin and the radiotracer. Recently, a positive immunostain-
ing for CgA in MTC has also been described: the staining for
CgA correlates with the areas staining positively for
calcitonin (Schmid et al., 1987). CgA is released by
neuroendocrine tumours without physiological neuroendo-
crine stimuli and is present in a significant amount in the
intracellular matrix of such tumours.
Several studies have shown the capability of ISG
performed with '"'I or "'In-labelled anti-CEA MAb to
visualise MTC recurrences (Berche et al., 1982; Reiners et
al., 1986; Edington et al., 1988; Manil et al., 1989; Zanin et
al., 1990; O'Byrne et al., 1992; Vuillez et al., 1992). However,
after injection of directly labelled MAb, image interpretation
is sometimes difficult because of non-specific bone marrow,
vascular and liver activity (Peltier et al., 1993). In CEA-
positive tumours, gliomas and lung cancers (Paganelli et al.,
1994a; Dosio et al., 1994), and more recently in neuroendo-
crine tumours using an anti-CgA MAb (Colombo et al.,
1993), the avidin-biotin pretargeting method provides good
results and offers several advantages over the administration
of directly labelled MAbs. A fast label clearance and removal
of circulating antibodies, with low background radioactivity
levels, and the preservation of MAb immunoreactivity
(Paganelli et al., 1991) were demonstrated. In addition the
second and third step of this three-step protocol can be
common to all studies, irrespective of the specificity of the
anti-tumour MAb, and potentially useful MAbs can be
injected in sequence or even in combination, as we did, as the
first step. In this way, radiolabelled biotin can serve as a
single carrier of diagnostic or therapeutic radionuclides in
patients receiving cocktails of antibodies.
In the present study, four patients underwent ISG using,
for the first step, a cocktail of MAbs that recognises different
tumour-associated antigens (CEA and CgA) (Fazio and
Paganelli, 1993; Matzku et al., 1989). As the activity
delivered to the tumour is low, the use of a cocktail would
enhance the possibility of targeting more tumour cells by
using different tumour antigens as targets. Thus, using a
cocktail of antibodies we could either avoid false-negative
studies that may occur when one of the two antigens is not
expressed, or provide an amplification of the signal from the*TC pretargeted P -nI
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tumour. given that more avidin can bind biotinylated MAbs
that recognised the two antigens expressed in different
tumour cells. Of the 55 histologically confirmed ISG
lesions. 50 turned out to be TP. two TN. two FP and two
FN. One patient (no. 7). who underwent ISG 2 months after
surgery for primary MTC. did not show tracer uptake. Ct
serum levels. both basal and after pentagastrin stimulation.
and neck US were normal in a 6 month period of follow-up.
Thus the patient can also be considered TN.
No relationship between CEA serum levels and ISG
sensitivity was found. Four patients who underwent anti-
CEA ISG studies had normal CEA serum levels and TP
scans. Thus. ISG using anti-CEA MAb is effective even when
Ct alone is elevated.
All primary tumours were visualised. In addition. a patient
with C-cell hyperplasia. considered a preneoplastic condition.
was correctly diagnosed. and in a patient with normal Ct serum
levels a pathological uptake ofthe tracer was demonstrated by
ISG and subsequently confirmed by histology.
Fifty out of 52 tumour recurrences (96%) were imaged
and confirmed by cytology or histology.
Tomographic ISG study was crucial for detecting small
lymph nodes. with a diameter of 4-7 mm. that were not
recognised as neoplastic by US. Moreover the presence of
blood activity. although low with respect to directly labelled
MAbs. could make it difficult to distinguish lymph node
activity from vascular background (see Figures 4-6) on
planar images. whereas using SPET the separation of tumour
from background activity is feasible.
A patient whose US and CT scans revealed a liver lesion
had a negative ISG liver scan. and histology subsequently
revealed the benign nature of the lesion.
One potential disadvantage of this pretargeting protocol is
the immunogenicity of avidin. The immunogenicity of
biotinylated antibodies and avidin was tested in only 11
patients. However, data available from 60 other patients
receiving, in similar protocols. biotinylated antibodies (i.e.
anti-tenascin. anti-CEA and anti-CgA) and avidin. comply
with the results of this study. In particular, none of the
patients studied developed an important response to mouse
immunoglobulin after the injection of 1 mg of biotinylated
IgG and 22% developed HAAR after the injection of 5-
6 mg of avidin (unpublished data).
In conclusion, pretargeted ISG with CEA and or CgA
MAb may be useful in MTC follow-up, when the only
marker of relapse is serum elevation of Ct. in order to
localise tumour recurrences. and in the early detection of
preneoplastic conditions. such as C-cell hyperplasia.
With this method, radiolabelled biotin can serve as a carrier
not only for diagnostic but also for therapeutic purposes.
However, radioactivity delivered per gram of tumour is still
below the optimal dose for radioimmunotherapy (Paganelli et
al., 1994b). A higher tumour radioactivity could be obtained by
using more biotinylated MAbs in the first step and streptavidin
in the second step, as this results in a better avidination of the
tumour. As avidin blood clearance is very fast, the longer
plasma t, . ofstreptavidin can convey more streptavidin and so
more radiolabelled biotin to the tumour. However, streptavidin
may be more immunogenic than avidin when injected in
humans (unpublished data). Methods to block this response are
currently under evaluation and it is anticipated that advances in
molecular biology and recombinant DNA technology will
contribute significantly to circumventing this problem. By
optimising the radioactivity channelled onto the tumour and by
labelling biotin with f-emitting isotopes. such as 9Y and '88Re,
antibody-guided therapy of small MTC recurrences may be
feasible.
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